Irene Rodriguez

[Bradbury Lab @BradburyLab]

Out now in @NatureComms! @I_Francos found that the presence of CSPGs in the injured spinal cord act via TLR4 signaling to prevent immune cells from entering a resolution phenotype, prolonging inflammation & limiting repair. Find it #OpenAccess here: https://t.co/ztZkMLfH6V 1/9

[Vicky Sanz-Moreno @VickySanzMoreno]

Check out our latest review on amoeboid cancer cells @TrendsCellBio @VittoriaGrazia8 @Omaiques @Irenitarh @QMBCI @CR_UK @Barts_Charity #actomyosin 🤩
The amoeboid state as part of the epithelial-to-mesenchymal transition programme https://t.co/UYe4UlVSCL

[Vicky Sanz-Moreno @VickySanzMoreno]

Great collaboration with Gilbert Fruhwirth! Congratulations to all authors on our pre-clinical pipeline to test migrastatics in melanoma!!real team effort🤩🤩 https://t.co/3FnJ9r3B29

[lkohlham @lkohlham]

🌟 @Irenitarh’s work and my first contribution to a publication in @VickySanzMoreno lab 🌟 showing that amoeboid cells are both invasive and proliferative! And contractility can regulate EMT-related transcriptional programs and stemness 🧫 🧬 @QMBCI @CR_UK
https://t.co/GSqHbXIQH1

[Camilla Cerutti ☮️ 😷 @ccamilla81]

Out today in @NatureComms
The work of @Irenitarh in @VickySanzMoreno Lab
👇https://t.co/rdus7JJAWA

[Vicky Sanz-Moreno @VickySanzMoreno]

Delighted to share the latest work from our lab 😀 Congratulations @Irenitarh and the team! @QMBCI @Barts_Charity @CR_UK @MSCActions #actomyosin #melanoma
WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion https://t.co/2BI0xhRNJH

[Vicky Sanz-Moreno @VickySanzMoreno]

Finally out! our latest work on cytoskeleton and therapy resistance in melanoma:
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance https://t.co/0MomXfc9oc